[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Yeg├╝ez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • Malignant neoplasms of the anus were excluded for the purposes of this study.
  • Intravenous drug abuse was the main risk factor for HIV.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / surgery. Adenocarcinoma / complications. Adult. Aged. Female. Humans. Lymphoma, Non-Hodgkin / complications. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Survival Rate


2. Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ: Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am J Clin Oncol; 2008 Feb;31(1):1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proteasome inhibitor bortezomib enhances the cytotoxic activity of fluoropyrimidines and platinum agents in vivo, and targeting of NF-kappaB may overcome chemotherapy resistance.
  • Three objective tumor responses were noted (squamous cell of anus, adenocarcinoma of unknown primary, adenocarcinoma of rectum).
  • As 1.6 mg/m(2) weekly of bortezomib is the maximum tolerated dose in single-agent studies, no further dose escalation was performed in this study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Boronic Acids / administration & dosage. Bortezomib. Capecitabine. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Male. Maximum Tolerated Dose. Middle Aged. Organoplatinum Compounds / administration & dosage. Pyrazines / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376220.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Organoplatinum Compounds; 0 / Pyrazines; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 69G8BD63PP / Bortezomib; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
3. Shintani F, Izumi M, Fujimura N: Neuroleptic malignant syndrome versus malignant disease: idiosyncratic or synchronous? Lancet; 2009 Jul 4;374(9683):90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Anus Neoplasms / diagnosis. Neuroleptic Malignant Syndrome / diagnosis
  • [MeSH-minor] Antidepressive Agents / adverse effects. Antimanic Agents / adverse effects. Bipolar Disorder / complications. Bipolar Disorder / drug therapy. Causality. Colonoscopy. Creatine Kinase / blood. Creatine Kinase, MB Form / blood. Diagnosis, Differential. Fatal Outcome. Fever / etiology. Humans. Lithium Carbonate / adverse effects. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroleptic malignant syndrome.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. LITHIUM CARBONATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577697.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antimanic Agents; 2BMD2GNA4V / Lithium Carbonate; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, MB Form
  •  go-up   go-down






Advertisement